tickdelta
Sign in
Screener / SEC EDGAR /CIK 0001555280 /10-K filed Feb 12, 2026, compared with Feb 13, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
BAXZTSISRGSOLVZBHBIIB
NYSE Health care · Pharmaceuticals

Zoetis ZTS

ZTS quote by TradingView
Employees
14,500
Headquarters
Parsippany, NJ
CEO
Kristin C. Peck
Next results
around Feb 11, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $9.5B through the costs to a net profit of $2.7B · income statement of the 10-K

28% net margin
Revenue to Gross profit: $6.8BRevenue to Cost of revenue: $2.7BGross profit to Net profit: $2.7BGross profit to Costs, tax, other: $4.1B Revenue: $9.5B REVENUE $9.5B +2% Y/Y Gross profit: $6.8B · 72% margin GROSS PROFIT $6.8B 72% margin Cost of revenue: $2.7B · 28% of revenue COST OF REVENUE $2.7B 28% of revenue Net profit: $2.7B · 28% margin NET PROFIT $2.7B 28% margin · +8% Y/Y Costs, tax, other: $4.1B · 44% of revenue COSTS, TAX, OTHER $4.1B 44% of revenue
Gross profit $6.8B 72% margin
Net profit $2.7B 28% margin · +8% Y/Y
The full income statement, year by year

ZTS among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 2.3%, above 20% of 59 peers (their median 7.2%) REVENUE GROWTH 2.3% · above 20% Gross margin: 71.6%, above 74% of 50 peers (their median 64.2%) GROSS MARGIN 71.6% · above 74% Net margin: 26.4%, above 92% of 59 peers (their median 9.5%) NET MARGIN 26.4% · above 92% FCF margin: 23.5%, above 85% of 55 peers (their median 15.2%) FCF MARGIN 23.5% · above 85%
ZTS Peer median Below the median

What changed

18 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 12, 2026 against Feb 13, 2025.

Risk factors
18 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Receivables growing faster than revenue
Receivables +20.8% vs revenue +2.3% (+18.5 pts)
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
2 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Receivables growing faster than revenue
    Receivables +20.8% vs revenue +2.3% (+18.5 pts)
  • Cash from operations $2.9B vs net income $2.7B (FY ending Dec 31, 2025)
9 more checks with nothing to note
  • Inventory +5.4% vs revenue +2.3% (+3.1 pts)
  • Same auditor in both 10-Ks: KPMG LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Evaluation of gross unrecognized tax benefits; Deductions from revenue related to the rebates accrual for the U.S. segment
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

18 paragraphs in Risk Factors that were not in the 10-K filed Feb 13, 2025. Quoted as filed.

All 18 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Our products generally receive regulatory approval based on data obtained in controlled clinical trials. After approval and launch, the products are used for longer periods of time by much larger numbers of animals worldwide, which may lead to identifying new safety or efficacy concerns. In addition, we or others may conduct…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Changes in trade policies, including the imposition of tariffs, sanctions, and other trade restrictions, may adversely affect our business.
  3. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    Current or future tariffs or other restrictive trade measures may raise the costs of raw materials, components or finished goods, which may adversely impact both our product offerings and our operational expenses. Our manufacturers, suppliers and distribution channels may also experience supply chain disruptions as a result of increased…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 13, 2025 10-K, ITEM 1A
    The current transition of our ERP system is a multi-year implementation process; transitioning to new systems, integrating new systems into current systems or any disruptions or malfunctions (including from circumstances beyond our control) affecting our information systems could cause critical information upon which we rely to be…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$8.1B$8.5B$9.3B$9.5B
Net income$2.1B$2.3B$2.5B$2.7B
Operating cash flow$1.9B$2.4B$3.0B$2.9B
Free cash flow$1.3B$1.6B$2.3B$2.3B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$9.5B ▲ 2.3% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

2 filings in the last 30 days · SEC EDGAR

All filings

About the company

Zoetis, Parsippany, NJ · from the 10-K filed Feb 12, 2026

Overview 1 Operating Segments 1 Products 3 International Operations 7 Sales and Marketing 7 Customers 7 Research and Development 8 Manufacturing and Supply Chain 8 Competition 9 Intellectual Property 9 Regulatory 10 Human Capital Management 12 Information about our Executive Officers 13 Environmental, Health and Safety 15 Available Information 15

Headquarters
Parsippany, NJ
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Nov 5, 2026

Employees, at the top of the page: "As of December 31, 2025, we had approximately 14,500 employees worldwide, which included approximately 6,800 employees in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 12, 2026 (open at SEC), compared with the 10-K filed Feb 13, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ZTS/export.csv") into a cell.